Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmodium glutathione reductase is a homodimeric flavoenzyme essential for the malaria parasite's antioxidant defense system. It catalyzes the reduction of oxidized glutathione disulfide (GSSG) to reduced glutathione (GSH) using NADPH, maintaining the intracellular redox balance necessary for parasite survival. While structurally similar to the human enzyme, the Plasmodium enzyme contains notable differences at ligand-binding sites, which are exploited for selective inhibitor design. Glutathione reductase is not essential for parasite asexual blood stage growth but becomes critical for the mosquito oocyst stage. It is a validated antimalarial drug target due to its indispensable role in the parasite's protection from oxidative stress and its structural divergence from the host enzyme.
Inhibition of glutathione reductase disrupts the parasite's redox balance, impairs antioxidant defense, and leads to oxidative stress and death of the malaria parasite.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium glutathione reductase.